drugset / Trial / NCT04099732

A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood

NCT04099732

Phase 1 Completed 26 enrolled Boehringer Ingelheim
Non-randomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of rosuvastatin (Reference 1, Part 1) and dabigatran (Reference 2, Part 2) given alone and together with BI 1358894 (Test 1, Test 2) following oral administration.

Timeline

Start
2019-10-07
Primary completion
2019-12-10
Completion
2019-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1358894 Small molecule Oral
Subject Rosuvastatin Small molecule Oral

Indications

No indication recorded.